Abstract

Although there are several decision aids for the treatment of localized prostate cancer (PCa), there are limitations in the consistency and certainty of the information provided. We aimed to better understand the treatment decision process and develop a decision-predicting model considering oncologic, demographic, socioeconomic, and geographic factors. Men newly diagnosed with localized PCa between 2010 and 2015 from the Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting database were included (n = 255,837). We designed two prediction models: (1) Active surveillance/watchful waiting (AS/WW), radical prostatectomy (RP), and radiation therapy (RT) decision prediction in the entire cohort. (2) Prediction of AS/WW decisions in the low-risk cohort. The discrimination of the model was evaluated using the multiclass area under the curve (AUC). A plausible Shapley additive explanations value was used to explain the model’s prediction results. Oncological variables affected the RP decisions most, whereas RT was highly affected by geographic factors. The dependence plot depicted the feature interactions in reaching a treatment decision. The decision predicting model achieved an overall multiclass AUC of 0.77, whereas 0.74 was confirmed for the low-risk model. Using a large population-based real-world database, we unraveled the complex decision-making process and visualized nonlinear feature interactions in localized PCa.

Details

Title
Explainable ML models for a deeper insight on treatment decision for localized prostate cancer
Author
Han, Jang Hee 1 ; Lee, Sungyup 2 ; Lee, Byounghwa 2 ; Baek, Ock-kee 2 ; Washington, Samuel L. 3 ; Herlemann, Annika 4 ; Lonergan, Peter E. 5 ; Carroll, Peter R. 6 ; Jeong, Chang Wook 7 ; Cooperberg, Matthew R. 3 

 Seoul National University Hospital, Department of Urology, Seoul, Republic of Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X) 
 Electronics and Telecommunications Research Institute (ETRI), Daejeon, Republic of Korea (GRID:grid.36303.35) (ISNI:0000 0000 9148 4899) 
 University of California, Department of Urology, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Epidemiology and Biostatistics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of California, Department of Urology, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); Ludwig-Maximilians-University of Munich, Department of Urology, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X) 
 University of California, Department of Urology, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); St. James’s Hospital, Department of Urology, Dublin, Ireland (GRID:grid.416409.e) (ISNI:0000 0004 0617 8280); Trinity College, Department of Surgery, Dublin, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705) 
 University of California, Department of Urology, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 Seoul National University Hospital, Department of Urology, Seoul, Republic of Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X); University of California, Department of Urology, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); Seoul National University College of Medicine, Department of Urology, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905) 
Pages
11532
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2838512674
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.